Navigation Links
Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Date:7/16/2009

f unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the sufficiency of Nile's available capital, timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are descr
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
8. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Inc. and Asahi Kasei,Medical Co., Ltd., who have ... use with Planova(TM) virus removal filters,have reached agreement ... Kasei Medical,s full ownership. The integration of,operations will ... TechniKrom, Inc., a,wholly owned subsidiary of Asahi Kasei ...
... Inc., a biotechnology company delivering breakthrough therapies in ... is a SILVER level sponsor of the 2009 ... conference, put on by the Alzheimer,s Association, is ... 2009 will take place July 11-16 in Vienna, ...
... 17 The Pittsburgh Life Sciences Greenhouse (PLSG), ... in western Pennsylvania, has surpassed the $13 million ... in direct investments in nearly 60 companies has ... the region. The PLSG continues to propel the ...
Cached Biology Technology:TechniKrom's Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical 2Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference 2The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum 2The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum 3The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum 4The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum 5
(Date:4/24/2014)... common plant puts out a welcome mat to bacteria seeking ... , The study published this week in the Proceedings ... during the battle between microbe and host that researchers can ... humble and oft-studied plant Arabidopsis puts out a ... as if a hostile army were unknowingly passing by a ...
(Date:4/23/2014)... This news release is available in French and ... woman? Male or female? In humans and other mammals, the difference ... Y chromosome. It is present only in males, where the two ... chromosomes. Thus, the Y is ultimately responsible for all the morphological ... not always been the case. A very long time ago, the ...
(Date:4/23/2014)... male black widow spiders prefer their female mates to ... preference by male spiders. , The study, ... a professor in UTSC,s Department of Biological Sciences, found ... males overwhelmingly chose to mate with well-fed, unmated females. ... a potential mate is well-fed and unmated by pheromones ...
Breaking Biology News(10 mins):How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Male or female? 2Male or female? 3Picky male black widow spiders prefer well-fed virgins 2
... and, new research shows, an infrared laser can make a ... and Vanderbilt University found that pulsed light can pace contractions ... the tissue. The work, "Optical pacing of the embryonic heart," ... Nature Photonics on Aug. 15, 2010. According to ...
... 27 BIO-key International, Inc. (OTC Bulletin Board: http://photos.prnewswire.com/prnh/20050509/BIOKEYLOGO ) ... What: , BIO-key International, Inc. Second Quarter ... Thursday, July 29, 2010 - 10:00 a.m. Eastern Time ... Live via phone by dialing 800-860-2442 and asking for the BIO-key call ...
... 13, 2010The easy accessibility of the eye and the ... offer hope for using gene therapy to provide long-term ... Human Gene Therapy, a peer-reviewed journal published by Mary ... replacement of a human gene to preserve photoreceptor function ...
Cached Biology News:A heart beats to a different drummer 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 3Promising results of gene therapy to treat diseases of the eye 2
... Situ Assay Kit is a fluorescent-based assay ... undergoing apoptosis. The kit is for research ... or therapeutic procedures. CHEMICON®s CaspaTag™ Pan-Caspase In ... to detect active caspases. The methodology is ...
... is a fluorescein-conjugated jetSI-ENDO ... at 520 nm), the powerful ... are used to determine the ... intracellular delivery and trafficking of ...
... Cellular uptake of long double stranded ... RNA interference in a diverse group of ... culture. RNA interference leads to the inhibition ... destruction of the target messenger RNA (mRNA). ...
... and reduced space requirements of the ... DNA analysis technology affordable .The benchtop ... of SEQUENOM's applications and assays, including: ... , Gene Expression Analysis (QGE) , ...
Biology Products: